TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the recommended dose of the sustained-release form of BPS (TRK-100STP low dose or high dose) in Japanese patients with CRF (Primary glomerular disease/nephrosclerosis).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Toray Industries, Inc
• Collaborator: Astellas Pharma Inc
• Treatments: Beraprost

Criteria

Inclusion Criteria:

• The CRF patient with primary glomerular disease or nephrosclerosis as the primary disease

• The patient with progressive CRF

Exclusion Criteria:

• The patient with secondary glomerular disease

• The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty kidney, polycystic kidney disease, or nephroureterolithiasis